Droxicam (BioDeep_00000178553)

   

human metabolite blood metabolite


代谢物信息卡片


8-methyl-5-(pyridin-2-yl)-3-oxa-9λ⁶-thia-5,8-diazatricyclo[8.4.0.0²,⁷]tetradeca-1(14),2(7),10,12-tetraene-4,6,9,9-tetrone

  化学式: C16H11N3O5S (357.0419)
中文名称: 屈昔康-d3
  谱图信息: 最多检出来源 Mus musculus(blood) 6.67%

分子结构信息

SMILES: CN1C2=C(C3=CC=CC=C3S1(=O)=O)OC(=O)N(C2=O)C4=CC=CC=N4
InChI: InChI=1S/C16H11N3O5S/c1-18-13-14(10-6-2-3-7-11(10)25(18,22)23)24-16(21)19(15(13)20)12-8-4-5-9-17-12/h2-9H,1H3


描述信息

M - Musculo-skeletal system > M01 - Antiinflammatory and antirheumatic products > M01A - Antiinflammatory and antirheumatic products, non-steroids > M01AC - Oxicams
C78272 - Agent Affecting Nervous System > C241 - Analgesic Agent > C2198 - Nonnarcotic Analgesic
D018373 - Peripheral Nervous System Agents > D018689 - Sensory System Agents
D002491 - Central Nervous System Agents > D000700 - Analgesics
D000893 - Anti-Inflammatory Agents
D018501 - Antirheumatic Agents

同义名列表

5 个代谢物同义名

8-methyl-5-(pyridin-2-yl)-3-oxa-9λ⁶-thia-5,8-diazatricyclo[8.4.0.0²,⁷]tetradeca-1(14),2(7),10,12-tetraene-4,6,9,9-tetrone; 5-Methyl-3-(pyridin-2-yl)benzo[5,6][1,2]thiazino[3,4-e][1,3]oxazine-2,4(3H,5H)-dione 6,6-dioxide; 5-Methyl-3-(2-pyridyl)-2H,5H-1,3-oxazino(5,6-c)(1,2)benzothiazine-2,4(3H)dione-6,6-dioxide; Droxicamum; Droxicam



数据库引用编号

8 个数据库交叉引用编号

分类词条

相关代谢途径

Reactome()

BioCyc()

PlantCyc()

代谢反应

个相关的代谢反应过程信息。

Reactome()

BioCyc()

WikiPathways()

Plant Reactome()

INOH()

PlantCyc()

COVID-19 Disease Map()

PathBank()

PharmGKB()

1 个相关的物种来源信息

在这里通过桑基图来展示出与当前的这个代谢物在我们的BioDeep知识库中具有相关联信息的其他代谢物。在这里进行关联的信息来源主要有：

  • PubMed: 来源于PubMed文献库中的文献信息，我们通过自然语言数据挖掘得到的在同一篇文献中被同时提及的相关代谢物列表，这个列表按照代谢物同时出现的文献数量降序排序，取前10个代谢物作为相关研究中关联性很高的代谢物集合展示在桑基图中。
  • NCBI Taxonomy: 通过文献数据挖掘，得到的代谢物物种来源信息关联。这个关联信息同样按照出现的次数降序排序，取前10个代谢物作为高关联度的代谢物集合展示在桑吉图上。
  • Chemical Taxonomy: 在物质分类上处于同一个分类集合中的其他代谢物
  • Chemical Reaction: 在化学反应过程中，存在为当前代谢物相关联的生化反应过程中的反应底物或者反应产物的关联代谢物信息。

点击图上的相关代谢物的名称，可以跳转到相关代谢物的信息页面。

亚细胞结构定位 关联基因列表


文献列表

  • M T Maya, J P Pais, J Ruas Da Silva, J A Morais. A comparative bioavailability study to estimate the influence of an antacid on droxicam pharmacokinetics. European journal of drug metabolism and pharmacokinetics. 1995 Oct; 20(4):275-9. doi: 10.1007/bf03190244. [PMID: 8983932]
  • M T Maya, J P Pais, J A Morais. A rapid method for the determination of piroxicam in plasma by high-performance liquid chromatography. Journal of pharmaceutical and biomedical analysis. 1995 Mar; 13(3):319-22. doi: 10.1016/0731-7085(95)01282-p. [PMID: 7619893]
  • K T Olkkola, A V Brunetto, M J Mattila. Pharmacokinetics of oxicam nonsteroidal anti-inflammatory agents. Clinical pharmacokinetics. 1994 Feb; 26(2):107-20. doi: 10.2165/00003088-199426020-00004. [PMID: 8162655]
  • A Bartlett, A Costa, L Martínez, R Roser, R Sagarra, J Sánchez. The effect of antacid and ranitidine on droxicam pharmacokinetics. Journal of clinical pharmacology. 1992 Dec; 32(12):1115-9. doi: NULL. [PMID: 1487550]
  • A Bartlett, A Costa, L Martinez, R Roser, R Sagarra, J Sanchez. Cross-over study of the bioavailability of a new NSAID (droxicam) versus piroxicam in healthy volunteers following single and multiple dose administration. European journal of drug metabolism and pharmacokinetics. 1992 Jul; 17(3):195-9. doi: 10.1007/bf03190145. [PMID: 1490488]
  • J Hosie, J Kelly, J Sánchez, A Bartlett, F J Harrison. A pharmacokinetic study to evaluate the profile of droxicam in elderly healthy volunteers after a single oral dose of 20mg. European journal of rheumatology and inflammation. 1991; 11(4):45-9. doi: NULL. [PMID: 1365490]
  • L Martínez, J Sánchez. Pharmacokinetic profile of droxicam. European journal of rheumatology and inflammation. 1991; 11(4):10-4. doi: NULL. [PMID: 1365484]
  • J Sánchez, L Martínez, J García-Barbal, R Roser, A Bartlett, R Sagarra. The influence of gastric emptying on droxicam pharmacokinetics. Journal of clinical pharmacology. 1989 Aug; 29(8):739-45. doi: 10.1002/j.1552-4604.1989.tb03409.x. [PMID: 2778095]
  • L Martínez, J Sánchez, R Roser, J García-Barbal, A Bartlett, J Estruch, R Sagarra, S Puig, A Costa. Comparative study of the multiple dose pharmacokinetics and the tolerance of a new NSAID (droxicam) versus piroxicam in healthy volunteers. Methods and findings in experimental and clinical pharmacology. 1988 Nov; 10(11):729-37. doi: NULL. [PMID: 3221746]
  • J Esteve, L Martínez, R Roser, R Sagarra. Effects of droxicam on in vivo prostaglandin synthesis and ex vivo platelet aggregation. Methods and findings in experimental and clinical pharmacology. 1987 Apr; 9(4):209-13. doi: NULL. [PMID: 3110512]
  • A Esteve, L Martínez, R Roser, R Sagarra. Pharmacokinetics of droxicam in rat and dog. Methods and findings in experimental and clinical pharmacology. 1986 Jul; 8(7):423-9. doi: NULL. [PMID: 3762266]